LONDON, Oct. 23, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage global radiopharmaceutical company, today announced encouraging preliminary data from its ongoing Phase 1 dose-escalation study of [225Ac]Ac-FL-020, an investigational prostate-specific membrane antigen ("PSMA")-targeted alpha radiopharmaceutical, in patients with metastatic castration-resistant prostate cancer ("mCRPC"). The data are being presented as an E-Poster at the European Society for Medical Oncology ("ESMO") Congress 2026 in Madrid, Spain.

LONDON, Oct. 19, 2026 -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage global radiopharmaceutical company, today announced first-in-human imaging data for [111In]In-FL-261, its c-MET-targeted theranostic radionuclide drug conjugate ("RDC") program, in a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear Medicine ("EANM"), which is being held October 17 to 21, 2026, in Vienna, Austria.

LONDON, Sept. 9, 2026 -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for [225Ac]Ac-FL-261 and that the program has received Australian Human Research Ethics Committee ("HREC") approval and completed the Clinical Trial Notification ("CTN") process with Therapeutic Goods Administration ("TGA"). These clearances enable Full-Life to advance a Phase 1 clinical trial of [225Ac]Ac-FL-261 in the United States and Australia in patients with c-MET-expressing non-squamous non-small cell lung cancer ("nsNSCLC").

Gembloux, Belgium – August 20, 2026 – Full-Life Technologies (“Full-Life”, the “Company”), a fully integrated clinical-stage global radiotherapeutics company, today announced the completion of construction of its state-of-the-art manufacturing facility in Gembloux, Belgium, and the receipt of authorization to begin the commissioning and initial ramp-up phase of the facility’s accelerator

London, United Kingdom - August 14, 2026 - Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated clinical-stage global radiotherapeutics company, today announced its participation in ESMO Congress 2026, taking place in Madrid, Spain from October 23 to 27, 2026, and the 39th Annual Congress of the European Association of Nuclear Medicine ("EANM"), taking place in Vienna, Austria from October 17 to 21, 2026. The Company will present data from its PSMA-targeted alpha radioconjugate [225Ac]Ac-FL-020 at ESMO and from its c-MET-targeted theranostic RDC program FL-261 at EANM, where Full-Life will also host Booth 420 in Hall X-4.